J. Aigner

Omission of Axillary Dissection According to ACOSOG Z0011: Impact on Adjuvant Treatment Recommendations

A. Schneeweiss, C. Sohn, F. Marmé, 2013, Annals of Surgical Oncology.

Long-term remission in a patient with heavily pretreated, advanced ovarian cancer achieved by bevacizumab and metronomic cyclophosphamide treatment.

A. Schneeweiss, C. Sohn, P. Hallscheidt, 2011, Anti-cancer drugs.

Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: Long‐term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials

A. Schneeweiss, D. Jäger, C. Sohn, 2013, International journal of cancer.

Abstract P3-06-19: Ki-67 mRNA as a predictor for response to neoadjuvant chemotherapy in primary breast cancer

A. Schneeweiss, P. Altevogt, F. Marmé, 2012 .

The role of neoadjuvant chemotherapy in the management of primary breast cancer.

A. Schneeweiss, C. Sohn, F. Marmé, 2011, Minerva ginecologica.

Abstract P3-06-08: Ki-67 mRNA as a predictor for response to neoadjuvant chemotherapy in primary breast cancer

A. Schneeweiss, P. Altevogt, F. Marmé, 2012 .

Nab-Paclitaxel monotherapy as a treatment of patients with metastatic breast cancer in routine clinical practice.

A. Schneeweiss, F. Schuetz, F. Marmé, 2013, Anticancer research.